David Liberati’s Post

At Clora, we’re dedicated to fostering innovation and collaboration within the biotech community. That’s why we’re thrilled to share highlights from the recent Bio-IT World Conference where our Founder & CEO, Rahul Chaturvedi moderated an insightful panel discussion on “Strategies for Biotech Success: Insights on Raising Capital from CEOs and VCs.” In an ever-evolving landscape, navigating capital acquisition is paramount for biotech companies. Rahul led the discussion, delving into recent shifts in funding trends, anticipating market expectations, and providing invaluable and actionable insights on selecting the right investors amidst competitive markets. Missed the discussion? Reach out / comment below ⬇ to learn more about how Clora is driving innovation and collaboration in the biotech landscape. 🌟 Many thanks to the amazing panelists - Kimberly Nearing from BVCF Management Ltd, Trevor Perry from Selas Ventures, Jami Rubin from Boundless Bio and ARCH Venture Partners, Chris Shibutani MD MBA from Goldman Sachs, and Scott Megaffin from Adiso Therapeutics. 🌟 #Biotech #BioITWorld #Clora #VC

🌡️ Team Medrio just took a temperature check on the state of funding for #Biopharma and #Biotech. While venture capital investment is up from 2023, it's now spread across fewer deals. In fact, the total deal count for the first quarter of 2024 was the lowest it's been since Q3 2018. So, how can emerging teams with limited resources secure funding when venture capital firms are being so cautious? Our outlook report with BioPharma Dive reveals that quality clinical trial data could be the answer. Learn why data is more important than ever to attract investor interest and what other financial trends are driving the market. Download the report here: https://bit.ly/3SX8iKx

📣 Application call for our early-stage startups in drug development and delivery! 🗓️ Hand in your pitch deck until June 16, 2024 All details in the post below. #startups #entrepreneurship #lifesciences

Micropep Technologies Raises $29M in Series B Funding and Unveils Krisalix, its Proprietary Discovery Platform New Investment Round to Fuel Micropep’s Mission of Tackling Global Food Production Challenges with Innovative, Sustainable Micropeptide Solutions  Micropep Technologies (Micropep), the global leader in micropeptide technology, today announced a $29 million Series B funding round along with its proprietary discovery platform, Krisalix. The round was led by Zebra Impact Ventures, and Bpifrance Green Tech Investment, BPIFRANCE INVESTISSEMENT. All existing investors, Fall Line Capital, FMC Ventures, Sofinnova Partners, Supernova Invest, and IRDI Capital Investissement also participated, bringing the company’s total funding to more than $51.8 million Micropep plans to use the Series B funding to accelerate go-to-market strategy through partnerships, complete the regulatory studies of the first biofungicide molecule, and expand its pipeline of micropeptide active ingredients on the Krisalix™ platform. To read more: https://lnkd.in/dym7DDAV Guillaume Baxter, Michael Krel, Thomas LAURENT, Mikael Courbot, Jean-Philippe combier, Baptiste Tellier, Romain Sautrau, Lionel Artusio-Payot, Edouard Combette, Ingrid BOUVART - Grienenberger

Funding high-growth biotech ventures with life-changing potential is key.

A survey of 100 biotech leaders by Fierce Biotech shows that respondents were generally confident in meeting their next investment milestone, but clinical development challenges still exist. Learn more about what to know for the industry's new era: #biotech | #biotechnology

The #biopharma industry is always in need of talented minds to take promising pipelines to the clinic and beyond. A good biotech founder is able to cope with change and failure and has proven their expertise in hitting milestones, be it in the lab or when raising funds to bring their technologies and therapies to market. Labiotech.eu reached out to venture capitalists Novo Holdings Ltd and ELAIA to nominate prominent founders in the European biopharma industry who are committed to bringing potentially life-changing treatments to patients. Find out more via https://lnkd.in/ebsW6S54 #biopharmaleadership #innovatorsinbiotech #VCsinbiotech #healthcareinnovation #drugdevelopment #biotechentrepreneurs #pharmastartups #BiotechInnovation #LifeSciences #HealthcareStartups #PharmaLeadership #BiotechInvesting #ClinicalTrials #HealthTech #DrugDiscovery #VentureCapital

💰 Biotech Early Round Funding Activity ($1M+) - 1H 2024 We analyzed early-round biotech funding data from our online BiopharmIQ platform. See the recent funding activity: https://lnkd.in/g6rEmde3 Early round = Angel/pre-Seed, Seed, Series A 1st half 2024 Not surprisingly: ⇒ U.S. was at the top of the list (29 companies). Surprising? ⇒ UK (9 co) and China (9 co) had almost 1/3 as many companies as U.S. ⇒ Switzerland (7 co) was next on the list. ⇒ Canada (4 co) had twice as many companies as France (2 co). ⇒ Germany has 0 companies. For more details and more graphical data, see our blog post https://lnkd.in/giriKX84 Have questions or want to schedule an online demo? Contact marketing@biopharmiq.com

Shared lab spaces are a great way to reduce costs and accelerate progress for biotech start-ups. These spaces provide a streamlined launchpad complete with benches and a diverse network of industry mentors. If you're interested in learning more about co-working labs and how they can benefit your biotech start-up, check out the link below. #biotech #coworkinglabs

The #biotech sector just got another boost, with venBio raising $528M for new investments—showing a strong belief in the potential of #lifesciences companies. What's interesting to me about their approach is that they're looking at all stages of drug development, from early research to late-stage clinical trials. This is a good lesson for anyone interested in #biotechstocks: consider a company's entire pipeline, not just their lead product. This can help spread out risk and potentially increase the chances of backing a winner! https://loom.ly/mwlxZdc